ImmunityBio (IBRX) Revenue (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Revenue data on file, last reported at $44.2 million in Q1 2026.

• Revenue for Q1 2026 came in at $44.2 million, up 167.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $141.0 million (up 351.53% YoY), and the FY2025 annual result was $113.3 million, up 668.31% from the prior year.
• Revenue climbed to $44.2 million in Q1 2026 per IBRX's latest filing, from $38.3 million in the prior quarter.
• Over five years, Revenue peaked at $44.2 million in Q1 2026 and troughed at $14000.0 in Q1 2022.
• A 5-year average of $10.2 million and a median of $360000.0 in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2025: Revenue plunged 89.93% in 2022, then jumped 41192.5% in 2025.
• A 5-year view of Revenue shows it stood at $73000.0 in 2022, then soared by 90.41% to $139000.0 in 2023, then soared by 5333.09% to $7.6 million in 2024, then soared by 406.95% to $38.3 million in 2025, then climbed by 15.47% to $44.2 million in 2026.
• Business Quant data shows IBRX's Revenue at $44.2 million in Q1 2026, $38.3 million in Q4 2025, and $32.1 million in Q3 2025.